The global musculoskeletal diseases treatment market is expected to reach US$ 5,730.8 Mn in 2025 from US$ 3,837.9 in 2017. The musculoskeletal diseases treatment market is estimated to grow with a CAGR of 5.3% from 2018-2025.
The global musculoskeletal diseases treatment market is expected to reach US$ 5,730.8 Mn in 2025 from US$ 3,837.9 in 2017. The musculoskeletal diseases treatment market is estimated to grow with a CAGR of 5.3% from 2018-2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. It is expected that major chunk of the demand is expected to generate from the above mentioned countries. Additionally, factors such as increasing focus of global industry players in India and Japan, funds in China are likely to propel growth of the market.
Get sample Research Copy at: https://www.theinsightpartners.com/sample/TIPMD00002090/
Musculoskeletal diseases treatment Market: Competitive Landscape and Key Development
The major players operating in the musculoskeletal diseases treatment market include General Electric, Koninklijke Philips N.V., Siemens AG, Canon Medical Systems Corporation, Hitachi, Ltd., Accuray Incorporated, MR Solutions, Alltech Medical Systems, Terason Division Teratech Corporation, and Echo-Son SA.
For instance, in September 2018, Royal Philips launched the Ingenia Ambition X 1.5T MR. The product is the latest advance in the Ingenia MRI portfolio, that comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis. The developments performed by the companies are helping the market to grow in the coming years.
The musculoskeletal disease treatment market by disease is segmented into arthritis, osteoarthritis, osteoporosis, spondylitis and others. In 2017, the arthritis segment held a largest market share of 43.2% of the musculoskeletal diseases treatment market, by disease. This segment is also expected to dominate the market in 2025 owing to The arthritis is the largest segment among the disease segment in the musculoskeletal diseases treatment market in 2017 and is also anticipated to hold the largest market in the year 2025 owing to the increasing prevalence of the disease across the globe. Furthermore, the spondylitis segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2025.
On the basis of distribution channel, the musculoskeletal disease treatment market is segmented into computed tomography, magnetic resonance imaging, ultrasound and others. The computed tomography segment is anticipated to grow at a CAGR of 5.4% during the forecast period. The growth of computed tomography segment is primarily driven by increasing product innovation in the field of CT by the market players as well as advances in CT scanning providing increased patient comfort. On the other side, the ultrasound is expected to witness fastest growth registering the CAGR of 5.7% in the global musculoskeletal diseases treatment market over the forecast period.
Download Sample PDF Report copy at: https://www.theinsightpartners.com/sample/TIPMD00002090/
The common type of arthritis is osteoarthritis, which affects approximately 31 million Americans. By the end of 2040, number of people expected to have doctor-diagnosed arthritis will be above 78 million. As per the report published in 2018 of Healthline Media, rheumatoid arthritis (RA) affects 41 in every 100,000 people per year. Approximately, 1.3 million Americans have RA. Women are about two to three times more likely to get RA than men. The lifetime risk of developing RA is 3.6% for women and 1.7% for men. However, RA can strike at any age even small children can get it. Smoking is the mostly associated risk factor when it comes to the onset of RA in patients. A history of smoking is said to increase the risk of developing RA by as much 2.4%.
Musculoskeletal diseases treatment is performed with the help of most flexible diagnostic imaging modalities that has capabilities to characterize a wide range of parameters in the living subject as well as provide an exquisite spatial resolution. This technique has been explored by the numerous market players to achieve remarkable precision through extensive innovation in the product design and features. Various recent technological developments are marked in the evolution of musculoskeletal diseases treatment techniques over the past few years.
For instance, in June 2018, Konica Minolta Healthcare Americas, Inc., launched the SONIMAGE MX1 portable ultrasound system, developed for musculoskeletal (MSK) and orthopedic practices, interventional guidance and outpatient centers. SONIMAGE MX1 is made with power, portability that physicians need to make a confident and efficient diagnosis at the point-of-care. In March 2018, Philips introduced a new 3-tesla MRI scanner named Ingenia Elition 3.0T at the ECR 2018 in Vienna. Thus, the innovative steps and technological advancements undertaken by new entrants as well as established market players to improve the quality and efficacy of musculoskeletal diseases treatment scans is expected to favor the growth of the market in the years to come.
Place a Purchase Order to Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPMD00002090/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com